全文获取类型
收费全文 | 9844篇 |
免费 | 1162篇 |
国内免费 | 559篇 |
专业分类
耳鼻咽喉 | 50篇 |
儿科学 | 45篇 |
妇产科学 | 76篇 |
基础医学 | 1287篇 |
口腔科学 | 101篇 |
临床医学 | 1217篇 |
内科学 | 1573篇 |
皮肤病学 | 73篇 |
神经病学 | 503篇 |
特种医学 | 388篇 |
外国民族医学 | 19篇 |
外科学 | 1078篇 |
综合类 | 1460篇 |
现状与发展 | 7篇 |
预防医学 | 636篇 |
眼科学 | 84篇 |
药学 | 1085篇 |
38篇 | |
中国医学 | 854篇 |
肿瘤学 | 991篇 |
出版年
2024年 | 10篇 |
2023年 | 192篇 |
2022年 | 330篇 |
2021年 | 685篇 |
2020年 | 613篇 |
2019年 | 514篇 |
2018年 | 517篇 |
2017年 | 465篇 |
2016年 | 463篇 |
2015年 | 701篇 |
2014年 | 812篇 |
2013年 | 745篇 |
2012年 | 939篇 |
2011年 | 943篇 |
2010年 | 625篇 |
2009年 | 526篇 |
2008年 | 518篇 |
2007年 | 482篇 |
2006年 | 421篇 |
2005年 | 416篇 |
2004年 | 117篇 |
2003年 | 123篇 |
2002年 | 93篇 |
2001年 | 55篇 |
2000年 | 45篇 |
1999年 | 46篇 |
1998年 | 35篇 |
1997年 | 29篇 |
1996年 | 28篇 |
1995年 | 21篇 |
1994年 | 17篇 |
1993年 | 14篇 |
1992年 | 3篇 |
1991年 | 1篇 |
1990年 | 3篇 |
1989年 | 7篇 |
1988年 | 2篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1984年 | 1篇 |
1983年 | 2篇 |
1982年 | 2篇 |
1979年 | 1篇 |
1964年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
Lei Qi Mingxing Wang Yuehui Jia Yuanyuan Wang Liangfang Xue Linlin Du Shuxiu Hao Shengqi Su Ruixiang Wang Huixin Sun Chen Feng Guijin Li Qingyu Zeng Cunqi Lv Jiacheng Li Qi Li Yunyan Zhang Tong Wang 《International journal of cancer. Journal international du cancer》2023,153(6):1172-1181
Information regarding the impact of the coronavirus disease 2019 (COVID-19) pandemic on cervical cancer in mainland China is lacking. We explored its impact on the hospital attendance of patients with primary cervical cancer. We included 1918 patients with primary cervical cancer who initially attended Harbin Medical University Cancer Hospital between January 23, 2019, and January 23, 2021. Attendance decreased by 31%, from 1135 in 2019 to 783 in 2020, mainly from January to June (𝜒2 = 73.362, P < .001). The percentage of patients detected by screening decreased from 12.1% in January-June 2019 to 5.8% in January-June 2020 (𝜒2 = 7.187, P = .007). Patients with stage I accounted for 28.4% in 2020 significantly lower than 36.6% in 2019 (𝜒2 = 14.085, P < .001), and patients with stage III accounted for 27.1% in 2020 significantly higher than 20.5% in 2019 (𝜒2 = 11.145, P < .001). Waiting time for treatment was extended from 8 days (median) in January-June and July-December 2019 to 16 days in January-June (𝜒2 = 74.674, P < .001) and 12 days in July-December 2020 (𝜒2 = 37.916, P < .001). Of the 179 patients who delayed treatment, 164 (91.6%) were for the reasons of the healthcare providers. Compared to 2019, the number of patients in Harbin or non-Harbin in Heilongjiang Province and outside the province decreased, and cross-regional medical treatment has been hindered. The COVID-19 pandemic has negatively impacted cervical cancer patient attendance at the initial phase. These results are solid evidence that a strategy and mechanism for the effective attendance of cervical cancer patients in response to public health emergencies is urgently needed. 相似文献
4.
目的 研究胸段食管癌逆向调强放射治疗(IMRT)中累及野照射与扩大野照射对危及器官(OAR)受照剂量的影响。方法 40例胸段食管癌患者分别行累及野靶区勾画和扩大野靶区勾画并勾画危及器官,制定IMRT计划,评估2个计划的靶区适形指数(CI)和均匀性指数(HI)及危及器官的剂量学参数,剂量学参数比较采用配对t检验。结果 2种计划的PTV均能满足处方剂量要求,PTV在CI、HI上相近(P = 0.317、0.130)。两组间平均肺剂量、两肺V5、两肺V20、两肺V30、脊髓Dmean、心脏Dmean、心脏Dmax、心脏V30、心脏V40、心脏V60差异均存在统计学意义(P < 0.01)。结论 胸段食管癌患者行累及野照射与扩大野比较,可降低正常器官的受照剂量,从而降低放射性损伤风险。 相似文献
5.
6.
Hyun Cheol Chung MD PhD Yoon-Koo Kang MD PhD Zhendong Chen MD Yuxian Bai MD Wan Zamaniah Wan Ishak MD Byoung Yong Shim MD Young Lee Park MD Dong-Hoe Koo MD PhD Jianwei Lu MD Jianming Xu MD Hong Jae Chon MD Li-Yuan Bai MD Shan Zeng MD Ying Yuan MD Yen-Yang Chen MD Kangsheng Gu MD Wen Yan Zhong PhD Shu Kuang MD Chie-Schin Shih MD Shu-Kui Qin MD PhD 《Cancer》2022,128(5):995-1003
7.
Tianshu Liu Yuxian Bai Xiaoyan Lin Wei Li Jufeng Wang Xiaochun Zhang Hongming Pan Chunmei Bai Li Bai Ying Cheng Jingdong Zhang Haijun Zhong Yi Ba Wenwei Hu Ruihua Xu Weijian Guo Shukui Qin Nong Yang Jianwei Lu Kohei Shitara Ming Lei Mingshun Li Nicole Bao Tian Chen Lin Shen 《International journal of cancer. Journal international du cancer》2023,152(4):749-760
First-line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; <1 year). We report efficacy and safety results from Chinese patients in the phase III global CheckMate 649 study of nivolumab plus chemotherapy vs chemotherapy for the first-line treatment of GC/GEJC/esophageal adenocarcinoma (EAC). Chinese patients with previously untreated advanced or metastatic GC/GEJC/EAC were randomized to receive nivolumab (360 mg Q3W or 240 mg Q2W) plus chemotherapy (XELOX [capecitabine and oxaliplatin] Q3W or FOLFOX [oxaliplatin, leucovorin and 5-fluorouracil] Q2W), nivolumab plus ipilimumab (not reported) or chemotherapy alone. OS, blinded independent central review-assessed progression-free survival (PFS), objective response rate (ORR), duration of response (DOR) and safety are reported. Of 1581 patients enrolled and randomized, 208 were Chinese. In these patients, nivolumab plus chemotherapy resulted in clinically meaningful improvement in median OS (14.3 vs 10.2 months; HR 0.61 [95% CI: 0.44-0.85]), median PFS (8.3 vs 5.6 months; HR 0.57 [95% CI: 0.40-0.80]), ORR (66% vs 45%) and median DOR (12.2 vs 5.6 months) vs chemotherapy, respectively. The safety profile was acceptable, with no new safety signals observed. Consistent with results from the global primary analysis of CheckMate 649, nivolumab plus chemotherapy demonstrated a clinically meaningful improvement in OS and PFS and higher response rate vs chemotherapy and an acceptable safety profile in Chinese patients. Nivolumab plus chemotherapy represents a new standard first-line treatment for Chinese patients with non-HER2-positive advanced GC/GEJC/EAC. 相似文献
8.
Yan Gao MD Yizhen Liu MD PhD Yafei Wang MD Qingyuan Zhang MD Depei Wu MD Xu Ye MD Jianqiu Wu MD Wei Xu MD Jianfeng Zhou MD Yu Yang MD Hong Cen MD Feng Zhang MD Ying Xiang MD Xiaoqiong Tang MD Kaiyang Ding MD JinYing Lin MD Lei Ma MD Shunqing Wang MD Hao Yu MD Yang Zhao MD Bin Song MD Fangfang Lv MD Huiqiang Huang MD 《Cancer》2023,129(4):551-559
9.
目的:探讨血清糖类抗原125(carbohydrate antigen 125,CA125)、人附睾蛋白4(human epididymis protein 4,HE4)、中性粒细胞与淋巴细胞比值(neutrophil-lymphocyte ratio,NLR)联合检测在子宫内膜癌诊断中的作用。方法:选取42例子宫内膜癌患者、50例子宫内膜良性疾病患者和50例健康体检人群。采用SYSMEX XN550全自动血液分析仪计数术前外周血中性粒细胞和淋巴细胞,计算NLR;采用Maglumi4000全自动化学发光仪检测术前血清CA125、HE4水平。采用ROC曲线分析CA125、HE4、NLR和三者联合指标在诊断子宫内膜癌中的作用。结果:外周血NLR在健康组、良性组和子宫内膜癌组中逐渐增高,且差异有统计学意义(P<0.05);子宫内膜癌组HE4表达量显著高于良性组与健康组(P<0.05),而良性组与健康组之间差异无统计学意义(P>0.05);CA125表达量在三组中差异无统计学意义(P>0.05)。CA125、HE4、NLR及三者联合标记物的AUC分别为0.530、0.733、0.795、0.823,当分别取它们的临界值时,特异性分别为70.8%、85.1%、61.7%、83.0%,敏感性分别为40.0%、63.3%、86.7%、73.3%。单项指标NLR的敏感性最高,HE4的特异性最高,联合指标的特异性和敏感性都很高。结论:术前血清CA125、HE4和NLR联合检测具有较高的特异性和敏感性,联合检测可以互为补充,提高子宫内膜癌的诊断准确率,对子宫内膜癌的诊断具有指导意义。 相似文献